Citations

Showing 10 of 108162 citations.

Dorsal Root Ganglion Stimulation for Erythromelalgia Related Foot Pain: A Case Report and Review of the Literature
Hagedorn, Jonathan M. , Canzanello, Nicholas , Lamer, Tim J. , Hagedorn, Jonathan M

Mayo Clinic

Pain Practice | January 28, 2021 | Volume: 21 | Issue: 6 | Pages: 698-702

10.1111/papr.12998 | PMID 33508884 Get It

Abstract Erythromelalgia is a rare neurovascular disorder characterized by erythema, warmth, and episodic burning pain, often felt in the face, hands, and feet. Symptoms are typically worse with heat, exercise, stress, and during the overnight hours. Management often requires a multidisciplinary approach, including pain trigger avoidance, cool water baths, and topical and oral neuropathic medications. The use of spinal cord stimulation has been described in multiple case reports with success reported out to 24 months. To our knowledge, the use of dorsal root ganglion (DRG) stimulation for erythromelalgia‐related pain has not been described. Herein, we present a case of erythromelalgia‐related pain at the bilateral plantar surfaces of the feet, which was treated successfully with bilateral sacral S1 nerve root DRG stimulation.
Utility of the CHA2DS2-VASc score for predicting ischaemic stroke in patients with or without atrial fibrillation: a systematic review and meta-analysis
Siddiqi, Tariq Jamal , Usman, Muhammad , Rihal, Charanjit S. , Usman, Muhammad Shariq , Shahid, Izza , Ahmed, Jawad , Khan, Safi U. , Ya’qoub, Lina , Rihal, Charanjit S. , Alkhouli, Mohamad

Mayo Clinic

European Journal of Preventive Cardiology | January 28, 2021 | Volume: 29 | Issue: 4 | Pages: 625-631

10.1093/eurjpc/zwab018 | PMID 33693717 Get It

Abstract Aims Anticoagulants are the mainstay treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), and the CHA2DS2-VASc score is widely used to guide anticoagulation therapy in this cohort. However, utility of CHA2DS2-VASc in NVAF patients is debated, primarily because it is a vascular scoring system, which does not incorporate atrial fibrillation related parameters. Therefore, we conducted a meta-analysis to estimate the discrimination ability of CHA2DS2-VASc in predicting ischaemic stroke overall, and in subgroups of patients with or without NVAF. Methods and results PubMed and Embase databases were searched till June 2020 for published articles that assessed the discrimination ability of CHA2DS2-VASc, as measured by C-statistics, during mid-term (2–5 years) and long-term (>5 years) follow-up. Summary estimates were reported as random effects C-statistics with 95% confidence intervals (CIs). Seventeen articles were included in the analysis. Nine studies (n = 453 747 patients) reported the discrimination ability of CHA2DS2-VASc in NVAF patients, and 10 studies (n = 138 262 patients) in patients without NVAF. During mid-term follow-up, CHA2DS2-VASc predicted stroke with modest discrimination in the overall cohort [0.67 (0.65–0.69)], with similar discrimination ability in patients with NVAF [0.65 (0.63–0.68)] and in those without NVAF [0.69 (0.68–0.71)] (P-interaction = 0.08). Similarly, at long-term follow-up, CHA2DS2-VASc had modest discrimination [0.66 (0.63–0.69)], which was consistent among patients with NVAF [0.63 (0.54–0.71)] and those without NVAF [0.67 (0.64–0.70)] (P-interaction = 0.39). Conclusion This meta-analysis suggests that the discrimination power of the CHA2DS2-VASc score in predicting ischaemic stroke is modest, and is similar in the presence or absence of NVAF. More accurate stroke prediction models are thus needed for the NVAF population.
Statistical Issues in Tumor Marker Studies
Pajak, Thomas F., Clark, Gary M. , Hammond, M. Elizabeth H. , Clark, Gary M., Sargent, Daniel J. , McShane, Lisa M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 7 | Pages: 1011-1015

10.5858/2000-124-1011-siitms | PMID 10888777 Get It

Abstract Context. —Inferences from tumor marker studies are complicated by a variety of statistical concerns, which can make proper interpretation of results difficult. This article focuses on important issues that should be addressed when designing, conducting, and analyzing tumor marker studies. Objective. —To highlight the importance of considering statistical significance, risk ratios, statistical power, reproducibility, multiple testing, confirmatory studies, and missing data in the design of marker studies used for prognosis. Results. —Suggestions are provided for more effectively conducting marker studies. These include more careful attention to adequacy of the number of subjects for a marker study and improved documentation and standardization of assay methods. The importance of complete reporting of study results and description of the statistical analysis methods used is also emphasized. Conclusion. —Cooperation among clinicians, laboratory scientists, and statisticians will be required to conduct statistically sound tumor marker studies and to facilitate prioritizing markers for new and confirmatory studies in an environment of limited patient and specimen resources.
Prognostic Factors in Colorectal Cancer
Fielding, L P, Burgart, Lawrence J., Conley, Barbara A. , Cooper, Harry S. , Hammond, M. Elizabeth, Henson, Donald E., Hutter, R. V. P., Nagle, Raymond B., Nielsen, Mary L., Welton, Mark L., Willett, Christopher G. , Compton, Carolyn C. , Hamilton, Stanley R. , Sargent, Daniel J. , Taylor, Clive R.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 7 | Pages: 979-994

10.5858/2000-124-0979-pficc | PMID 10888773 Get It

Abstract Background. —Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive factors (factors predicting response to therapy) in colorectal carcinoma was evaluated. A multidisciplinary group of clinical (including the disciplines of medical oncology, surgical oncology, and radiation oncology), pathologic, and statistical experts in colorectal cancer reviewed all relevant medical literature and stratified the reported prognostic factors into categories that reflected the strength of the published evidence demonstrating their prognostic value. Accordingly, the following categories of prognostic factors were defined. Category I includes factors definitively proven to be of prognostic import based on evidence from multiple statistically robust published trials and generally used in patient management. Category IIA includes factors extensively studied biologically and/or clinically and repeatedly shown to have prognostic value for outcome and/or predictive value for therapy that is of sufficient import to be included in the pathology report but that remains to be validated in statistically robust studies. Category IIB includes factors shown to be promising in multiple studies but lacking sufficient data for inclusion in category I or IIA. Category III includes factors not yet sufficiently studied to determine their prognostic value. Category IV includes factors well studied and shown to have no prognostic significance. Materials and Methods. —The medical literature was critically reviewed, and the analysis revealed specific points of variability in approach that prevented direct comparisons among published studies and compromised the quality of the collective data. Categories of variability recognized included the following: (1) methods of analysis, (2) interpretation of findings, (3) reporting of data, and (4) statistical evaluation. Additional points of variability within these categories were defined from the collective experience of the group. Reasons for the assignment of an individual prognostic factor to category I, II, III, or IV (categories defined by the level of scientific validation) were outlined with reference to the specific types of variability associated with the supportive data. For each factor and category of variability related to that factor, detailed recommendations for improvement were made. The recommendations were based on the following aims: (1) to increase the uniformity and completeness of pathologic evaluation of tumor specimens, (2) to enhance the quality of the data needed for definitive evaluation of the prognostic value of individual prognostic factors, and (3) ultimately, to improve patient care. Results and Conclusions. —Factors that were determined to merit inclusion in category I were as follows: the local extent of tumor assessed pathologically (the pT category of the TNM staging system of the American Joint Committee on Cancer and the Union Internationale Contre le Cancer [AJCC/UICC]); regional lymph node metastasis (the pN category of the TNM staging system); blood or lymphatic vessel invasion; residual tumor following surgery with curative intent (the R classification of the AJCC/UICC staging system), especially as it relates to positive surgical margins; and preoperative elevation of carcinoembryonic antigen elevation (a factor established by laboratory medicine methods rather than anatomic pathology). Factors in category IIA included the following: tumor grade, radial margin status (for resection specimens with nonperitonealized surfaces), and residual tumor in the resection specimen following neoadjuvant therapy (the ypTNM category of the TNM staging system of the AJCC/UICC). Factors in category IIB included the following: histologic type, histologic features associated with microsatellite instability (MSI) (ie, host lymphoid response to tumor and medullary or mucinous histologic type), high degree of MSI (MSI-H), loss of heterozygosity at 18q ( DCC gene allelic loss), and tumor border configuration (infiltrating vs pushing border). Factors grouped in category III included the following: DNA content, all other molecular markers except loss of heterozygosity 18q/DCC and MSI-H, perineural invasion, microvessel density, tumor cell–associated proteins or carbohydrates, peritumoral fibrosis, peritumoral inflammatory response, focal neuroendocrine differentiation, nuclear organizing regions, and proliferation indices. Category IV factors included tumor size and gross tumor configuration. This report records findings and recommendations of the consensus conference group, organized according to structural guidelines defined herein.
Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment
Basch, Ethan , Dueck, Amylou C. , Leahy, Allison B , Dueck, A. C. , Basch, Ethan , Leahy, Allison Barz

Mayo Clinic

Journal of Clinical Oncology | January 28, 2021 | Volume: 39 | Issue: 7 | Pages: 701-703

10.1200/jco.20.03375 | PMID 33507823 Get It

Impact of congenital diaphragmatic hernia on diaphragm muscle function in neonatal rats
Fogarty, Matthew J. , Enninga, Elizabeth Ann L. , Enninga, Elizabeth Ann L , Ibirogba, Eniola R. , Ruano, Rodrigo , Sieck, Gary C. , Fogarty, Matthew J

Mayo Clinic

Journal of Applied Physiology | January 28, 2021 | Volume: 130 | Issue: 3 | Pages: 801-812

10.1152/japplphysiol.00852.2020 | PMID 33507852 Get It

There are notable respiratory deficits related to congenital diaphragmatic hernia (CDH), yet the contribution, if any, of frank diaphragm muscle weakness to CDH is unexplored. Here, we use the well-established Nitrofen teratogen model to induce CDH in rat pups, followed by diaphragm muscle contractility and morphological assessments. Our results show diaphragm muscle weakness in conjunction with reduced muscle fiber density and size, contributing to CDH morbidity.
Morning Rounds Inpatient Test Availability
Novis, David A., Dale, Jane C.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 4 | Pages: 499-503

10.5858/2000-124-0499-mrita | PMID 10747303 Get It

Abstract Objectives. —To determine the success with which laboratories were able to report morning test results on time, the laboratory practice characteristics associated with improved success, and the degree of satisfaction among clinicians with the timeliness of laboratory service. Design. —Hospital laboratories participating in the College of American Pathologist Q-Probes laboratory quality improvement program prospectively calculated the percentages of morning-run complete blood cell count (CBC) and electrolyte results that were reported on or before predetermined reporting deadlines, completed questionnaires concerning their departments' practice characteristics as they related to performing morning blood work, and distributed to physician utilizers of morning laboratory services questionnaires evaluating physician satisfaction with laboratory services. Setting and Participants. —A total of 367 public and private institutions located in the United States (355), Canada (5), Australia (2), and 1 each in the United Kingdom, Spain, Brazil, Korea, and Guam. Main Outcome Measure. —The percentages of morning-run CBC and electrolyte results reported on or before predetermined reporting deadlines. Results. —Participants submitted data on 40 256 CBC and 39 604 electrolyte specimens. In aggregate, a total of 88.9% of these tests (90.2% of CBCs and 87.6% of electrolytes) were reported on or before the reporting deadlines that the participating laboratories set for themselves. Half of the participants reported 94.6% of their CBC results and 95.5% of their electrolyte results on or before their self-imposed reporting deadlines. No specific demographic features or departmental practice characteristics were associated with higher or lower rates of institutional reporting compliance. Most physician utilizers of early-morning laboratory test results believed that the laboratory is sensitive to and meets the needs of clinicians for timely reporting of early-morning test results. Conclusions. —Most laboratories are capable of reporting 95% of their routine morning laboratory tests on time, and most physicians are satisfied with their laboratories' morning testing service.
Redesigned Proficiency Testing Materials Improve Survey Outcomes for Prostate-Specific Antigen
Sokoll, Lori J. , Witte, David L., Klee, George G., Chan, Daniel W.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 11 | Pages: 1608-1613

10.5858/2000-124-1608-rptmis | PMID 11079010 Get It

Abstract Context. —Large disparities in prostate-specific antigen (PSA) results from different assays have been observed in the College of American Pathologists (CAP) Ligand Assay Survey, with interassay results varying severalfold. Survey specimens are predominately composed of free PSA and do not reflect the composition of typical patient specimens. Objectives. —To characterize a pilot material developed for CAP in which pooled sera samples were spiked with purified PSA and α 1 -antichymotrypsin–bound PSA at targeted concentrations and to compare it to CAP survey and reference materials. Design. —CAP survey, reference, and pilot materials were analyzed using 10 total PSA and 7 free PSA assays. These assays included Food and Drug Administration–approved assays and assays for research use only. Results. —Variability among the 10 total PSA methods was greatest for the 1997 ligand survey material (CV range, 56%–65%) followed by the pilot material (CV range, 10%–29%) and the reference material (CV range, 6%–13%). In contrast, interassay variability for the 7 free PSA methods was similar for the 3 preparations, with the exception of one specimen close to the limit of detection of the assays. As determined with the Hybritech Tandem-R method, the ligand survey specimens were essentially composed of all free PSA, whereas the reference and pilot materials were composed of approximately 10% and 35% free PSA, respectively. Conclusions. —The newly formulated pilot material prepared using a human base that contained defined concentrations of free PSA and α 1 -antichymotrypsin–bound PSA more closely resembled patient specimens and minimized differences among methods compared with the semen-supplemented original survey material.
Hantavirus Pulmonary Syndrome Is Distinguishable From Acute Interstitial Pneumonia
Colby, Thomas V. , Zaki, Sherif R., Feddersen, Richard M. , Nolte, Kurt B.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 10 | Pages: 1463-1466

10.5858/2000-124-1463-hpsidf | PMID 11035576 Get It

Abstract Context. —Hantavirus pulmonary syndrome (HPS) and acute interstitial pneumonia (AIP) can share similar clinical presentations. AIP is an acute, diffuse lung disease that has some clinical features suggesting a viral infection, although causative agent(s) have not been identified. Objective. —To clinically, histologically, and immunohistochemically compare cases of HPS to cases of AIP and to determine if any cases of AIP were actually examples of HPS. Design. —Seven cases of HPS and 9 cases of AIP were compared clinically and histologically by semiquantitative grading of features in lung tissue. The cases were also evaluated immunohistochemically for the presence of hantaviral antigens. Results. —Hantavirus pulmonary syndrome had a shorter clinical duration and more acute changes histopathologically; AIP was of longer clinical duration and was usually accompanied by histologic evidence of organization. Hantavirus pulmonary syndrome was distinguished by the presence of immature leukocytes in the pulmonary vasculature. No hantaviral antigens were identified immunohistochemically in the 9 case of AIP. Hantaviral antigens were identified in all 7 cases of HPS. Conclusion. —Cases of AIP and fatal cases of HPS can generally be distinguished on clinical and histologic grounds, and this distinction can be further confirmed immunohistochemically.
Neonatal Bilirubin Testing Practices
Dale, Jane C., Hamrick, Harvey J.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 10 | Pages: 1425-1428

10.5858/2000-124-1425-nbtp | PMID 11035569 Get It

Abstract Objective. —To characterize laboratory practices for neonatal bilirubin testing and to identify opportunities for improvement. Design. —A voluntary self-assessment questionnaire was used to assess the laboratory practices of 312 laboratories subscribing to the College of American Pathologists (CAP) Excel Chemistry Proficiency Testing Program. Results. —A range of preanalytic and analytic practices were reported. The most notable problems identified were the use of overly long capillary puncture devices (17.8%), failure to protect the specimen from light prior to analysis (3.4%), failure to use a control containing >171 μmol/L bilirubin (26.1%), use of single-level control (4.2%), and lack of established linearity limits (7.0%). Conclusion. —Opportunities exist to improve specimen collection, processing, and analysis for some physician-office and small-hospital laboratories.